CClinicalTrials.gg
CompletedNCT03283072SensoryFLOUpdated Aug 21, 2023Results posted

Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults

An interventional study of Intervention 1 and Intervention 2 in Sensitivity, sponsored by University of Florida. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by University of Florida · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Exposure to acute intermittent hypoxia (AIH) can facilitate of motor output but no studies of sensory effects has been reported.

Read the detailed description

Despite the strong results of motor studies, the affects of AIH on sensory function has not been established. We will use a commercially-available hypoxicator that can be programmed to achieve a targeted level of arterial oxygen saturation. We plan to compare 3 previously published protocols that have generated motor facilitation (and a sham condition) to characterize and effects on sensory function in healthy adults.

02

Conditions studied

  • Sensitivity

Browse trials for

Keywords

  • thermal threshold
  • pressure pain threshold
  • temporal summation
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18 to 40 years of age

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of cardiovascular disease (Hypertension, arrhythmias, coronary artery disease, congenital and valvar heart diseases)
  • Diagnosis of neuromuscular disease
  • Diagnosis of any neurological disease
  • Presence of concurrent medical illness including infection, fractures
  • Diagnosis of obstructive sleep apnea
  • Diagnosis of obstructive/restrictive lung disease
  • Diagnosis of exercise induced asthma
  • FEV1/FVC\<80% and/or FVC\<80% of predicted value indicating airway obstruction
  • Subjects on prednisolone therapy or selective serotonin reuptake inhibitor (SSRI) therapy will be excluded from the study as these pharmacological agents are known to amplify the effects of IH[22, 23]
  • Diagnosis of epilepsy or history of seizures and attention deficit disorders
  • Pregnancy
  • Diabetes
  • History of coagulation disorders
  • History of chronic pain
  • Body mass index(BMI)> 35kg/m2
  • Subjects on prescription medicines such as beta blockers and other drugs that are prescribed in any of the exclusionary disorders listed above.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham)

    Device: Intervention 1 · Device: Intervention 2 · Device: Intervention 3 · Device: Intervention 4 (sham)

  • Experimental
    Sequence 2

    Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia

    Device: Intervention 1 · Device: Intervention 2 · Device: Intervention 3 · Device: Intervention 4 (sham)

  • Experimental
    Sequence 3

    Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia

    Device: Intervention 1 · Device: Intervention 2 · Device: Intervention 3 · Device: Intervention 4 (sham)

  • Experimental
    Sequence 4

    15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia

    Device: Intervention 1 · Device: Intervention 2 · Device: Intervention 3 · Device: Intervention 4 (sham)

Interventions

  • DeviceIntervention 1

    15 bouts of 2mins:1min hypoxia:hyperoxia

  • DeviceIntervention 2

    15 bouts of 1mins:1min hypoxia:hyperoxia

  • DeviceIntervention 3

    8 bouts of 2mins:1min hypoxia:hyperoxia

  • DeviceIntervention 4 (sham)

    15 bouts of 1min:1min normoxia

05

What researchers measure

Primary outcomes

  1. Sensory Function

    Thermal thresholds. Average reported.

    Time frame: Every 10 minutes for 60 minutes post intervention, average reported

  2. Temporal Sensory Summation

    Temporal summation represents increases in ratings of pain intensity measured using a numeric pain rating scale (0-no pain to 100-worst pain imaginable) to repeated heat stimuli of the same intensity; that is, "summation" represents increases in participant ratings of pain despite the maintenance of a standard temperature and is calculated as the difference between pain rating 1 and pain rating 6. Positive difference scores indicate that pain reported increased over the 6 pulses of heat. Here, the average difference across participants and over time is reported.

    Time frame: Every 10 minutes for 60 minutes post intervention, average reported

  3. Sensory Function - Pressure

    Pressure threshold is the force at which the sensation of pressure first is considered painful by the participant, average reported

    Time frame: Every 10 minutes for 60 minutes post intervention, average reported

06

Results

Posted Aug 21, 2023

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started7555
Completed5555
Not completed2000

Outcome measures

PrimarySensory Function

Thermal thresholds. Average reported.

Time frame:
Every 10 minutes for 60 minutes post intervention, average reported
Reported as:
Mean · Degrees celsius
Sensory Function
Degrees celsiusIntervention 1Intervention 2Intervention 3Intervention 4 (Sham)
Sensory Function46.7 ± 1.546.4 ± 1.946.1 ± 1.945.9 ± 2.1
Statistical analysis
  • Intervention 1 vs Intervention 2 vs Intervention 3 vs Intervention 4 (Sham) · ANCOVA · p = 0.592Within, within repeated measures ANCOVA (gender as co-variate).
PrimaryTemporal Sensory Summation

Temporal summation represents increases in ratings of pain intensity measured using a numeric pain rating scale (0-no pain to 100-worst pain imaginable) to repeated heat stimuli of the same intensity; that is, "summation" represents increases in participant ratings of pain despite the maintenance of a standard temperature and is calculated as the difference between pain rating 1 and pain rating 6. Positive difference scores indicate that pain reported increased over the 6 pulses of heat. Here, the average difference across participants and over time is reported.

Time frame:
Every 10 minutes for 60 minutes post intervention, average reported
Reported as:
Mean · score on a scale
Temporal Sensory Summation
score on a scaleIntervention 1Intervention 2Intervention 3Intervention 4 (Sham)
Temporal Sensory Summation17.4 ± 13.311.7 ± 10.210.9 ± 11.211.9 ± 15.6
Statistical analysis
  • Intervention 1 vs Intervention 2 vs Intervention 3 vs Intervention 4 (Sham) · ANCOVA · p = 0.721Within, within repeated measures ANCOVA (gender as co-variate).
PrimarySensory Function - Pressure

Pressure threshold is the force at which the sensation of pressure first is considered painful by the participant, average reported

Time frame:
Every 10 minutes for 60 minutes post intervention, average reported
Reported as:
Mean · kilograms force
Sensory Function - Pressure
kilograms forceIntervention 1Intervention 2Intervention 3Intervention 4 (Sham)
Sensory Function - Pressure4.4 ± 3.44.6 ± 2.54.3 ± 2.84.3 ± 3.1
Statistical analysis
  • Intervention 1 vs Intervention 2 vs Intervention 3 vs Intervention 4 (Sham) · ANCOVA · p = 0.553Within, within repeated measures ANVOA (gender as covariate)

Adverse events

Collected over 2 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/22 (0%)0/22 (0%)0/22 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence 1Sequence 2Sequence 3Sequence 4Total
Mean26.4 ± 6.319.2 ± 1.120.8 ± 2.020.8 ± 2.122.0 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
Female433010
Male122510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
American Indian or Alaska Native00000
Asian32139
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White23319
More than one race00112
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
United States555520
07

Study locations

1 site
  • Unversity of Florida
    Gainesville, Florida 32611, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 18, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03283072
Lead sponsor
University of Florida
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Sep 18, 2017
Primary completion
Jul 6, 2020
Completion
Jul 6, 2020
Results posted
Aug 21, 2023
Last update
Aug 21, 2023

Study contacts

Mark D Bishop, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion